Travere Therapeutics (TVTX) Convertible Debt (2011 - 2026)

Travere Therapeutics has reported Convertible Debt for 15 years, with the latest figure at $312.1 million in Q1 2026.

• For the quarter ending Q1 2026, Convertible Debt changed 0.46% year-over-year to $312.1 million; the trailing twelve-month figure through Mar 2026 stood at $312.1 million (changed 0.46% YoY), and the FY2025 full-year result was $311.7 million, down 17.75% from the prior year.
• Convertible Debt for Q1 2026 stood at $312.1 million, roughly flat from $311.7 million in the prior quarter.
• The five-year high for Convertible Debt was $379.0 million in Q4 2024, with the low at $310.0 million in Q3 2024.
• Historically, Convertible Debt has averaged $353.4 million across 5 years, with a median of $375.1 million in 2022.
• Annual changes were most pronounced in 2022 — Convertible Debt surged 71.65% — and 2025, when it retreated 17.75%.
• Travere Therapeutics' Convertible Debt stood at $375.5 million in 2022, then grew by 0.46% to $377.3 million in 2023, then grew by 0.46% to $379.0 million in 2024, then dropped by 17.75% to $311.7 million in 2025, then climbed by 0.11% to $312.1 million in 2026.
• The last three Convertible Debt figures came in at $312.1 million (Q1 2026), $311.7 million (Q4 2025), and $311.4 million (Q3 2025), per Business Quant data.